RA
TTNP

Ransom Advisory’s Titan Pharmaceuticals TTNP Stock Holding History

Ransom Advisory’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$5 – 438
2025
Q3 		$5 Hold
1
– – ﹤0.01% 299
2025
Q2 		$4 Hold
1
– – ﹤0.01% 322
2025
Q1 		$4 Hold
1
– – ﹤0.01% 333
2024
Q4 		$3 Hold
1
– – ﹤0.01% 408
2024
Q3 		$5 Hold
1
– – ﹤0.01% 411
2024
Q2 		$6 Hold
1
– – ﹤0.01% 404
2024
Q1 		$7 Buy
+1
New +$7 ﹤0.01% 340

Other funds holding TTNP

CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $246M AUM 23.62% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Ransom Advisory's TTNP Position: Q4 2025 in Review

Ransom Advisory sold out of Titan Pharmaceuticals (TTNP) in Q4 2025, closing a stake of 1 share — an estimated $5 sold.

Ransom Advisory first reported a position in TTNP in Q1 2024 and held it in 7 quarters. The position peaked at $7 in Q1 2024. 4 funds tracked by Wall St. Rank hold TTNP as of Q4 2025.

  • Ransom Advisory reported no remaining Titan Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Ransom Advisory sold 1 Titan Pharmaceuticals share in Q4 2025, an estimated $5.
  • Ransom Advisory first reported a position in Titan Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • Ransom Advisory's Titan Pharmaceuticals position peaked at $7 in Q1 2024.
  • 4 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2025.

Based on Ransom Advisory's 13F filing for Q4 2025, filed 6 Jan 2026.